Sun Pharma Stock Analysis: ‘Golden Cross’ Signals

The price of Sun Pharma stock recently showed a positive change called a ‘Golden Cross.’ This happens when the shorter-term price trend rises above the longer-term trend. It’s like a signal that the stock might be heading upwards.

Key Points

• ‘Golden Cross’ indicates potential stock price increase.
• Sun Pharma’s 50-day average is rising over the 200-day average.
• Stock likely to trade positively above ₹1,718 currently.
• Support levels: ₹1,750, ₹1,737, and ₹1,718.
• Resistance levels: ₹1,850 and potentially ₹1,950.
• Aurobindo Pharma and Divi’s Labs also show ‘Golden Cross’ patterns.

A ‘Golden Cross’ is considered a good sign for investors. It suggests that the stock is gaining momentum. Sun Pharma’s prices are currently at ₹1,785.

Specifically, the stock’s 50-day moving average (50-DMA) is now above the 200-DMA. This means that the short-term trend is climbing above the longer-term trend. The 50-DMA is at ₹1,683, while the 200-DMA is at ₹1,681.

Earlier in the year, in March, Sun Pharma experienced a ‘Death Cross,’ which is the opposite of a ‘Golden Cross.’ During this period, the stock price dropped by around 6% to a low of ₹1,548. Investors should be aware of these shifts in trends.

Besides Sun Pharma, other pharmaceutical stocks like Aurobindo Pharma and Divi’s Laboratories are also showing similar ‘Golden Cross’ patterns. Aurobindo Pharma’s price is at ₹1,204 and Divi’s Labs is at ₹6,472. These patterns suggest that these stocks might also move upwards.

Sun Pharma is expected to trade with a positive bias in the near term, as long as the stock remains above ₹1,718. The stock’s price might test the upper part of the Bollinger Bands on a monthly scale, around ₹1,950.

Aurobindo Pharma’s price has risen by nearly 22% in the last three months. The stock is currently close to its 20-DMA support at ₹1,180. Investors should pay attention to these levels.

Divi’s Labs’ stock rebounded after testing the 50-DMA support. The stock at around ₹6,472 faces resistance near the 20-DMA at ₹6,570 and the trend line hurdle around ₹6,700.

Ultimately, stock market analysis can provide valuable insights, but it’s just one piece of the puzzle.

The formation of a ‘Golden Cross’ offers a signal, not a guarantee, of future stock performance.